Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$214K Buy
+3,878
New +$210K 0.02% 234
2021
Q2
Sell
-12,266
Closed -$547K 201
2021
Q1
$547K Sell
12,266
-80
-0.6% -$3.63K 0.11% 149
2020
Q4
$568K Sell
12,346
-9,240
-43% -$424K 0.13% 134
2020
Q3
$1.02M Sell
21,586
-480
-2% -$24.1K 0.26% 99
2020
Q2
$1.13M Buy
+22,066
New +$1.13M 0.3% 82
2017
Q4
Sell
-4,218
Closed -$214K 177
2017
Q3
$214K Buy
4,218
+6
+0.1% +$304 0.08% 161
2017
Q2
$227K Buy
4,212
+7
+0.2% +$373 0.08% 159
2017
Q1
$222K Buy
+4,205
New +$213K 0.08% 157
2016
Q4
Sell
-8,036
Closed -$433K 172
2016
Q3
$433K Buy
+8,036
New +$441K 0.17% 110

Other funds holding GSK

Rodgers Brothers's GSK Position: Q1 2026 in Review

Rodgers Brothers opened a new position in GSK (GSK) in Q1 2026: 3,878 shares worth $214K. The stake represents 0.02% of the portfolio and ranks #234 among its holdings. This is a return to the name: Rodgers Brothers previously reported a position in GSK as recently as Q1 2021.

Rodgers Brothers first reported a position in GSK in Q3 2016 and has held it in 9 quarters since. The position peaked at $1.13M in Q2 2020. 1,033 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Rodgers Brothers held 3,878 shares of GSK worth $214K as of Q1 2026.
  • GSK was a new Rodgers Brothers position in Q1 2026.
  • GSK made up 0.02% of Rodgers Brothers's portfolio in Q1 2026, its #234 holding.
  • Rodgers Brothers first reported a position in GSK in Q3 2016 and has held it in 9 quarters since.
  • Rodgers Brothers's GSK position peaked at $1.13M in Q2 2020.
  • 1,033 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Rodgers Brothers's 13F filing for Q1 2026, filed 14 May 2026.